Ketek

Nazione: Unione Europea

Lingua: inglese

Fonte: EMA (European Medicines Agency)

Compra

Foglio illustrativo Foglio illustrativo (PIL)
19-06-2019
Scheda tecnica Scheda tecnica (SPC)
19-06-2019

Principio attivo:

telithromycin

Commercializzato da:

Aventis Pharma S.A.

Codice ATC:

J01FA15

INN (Nome Internazionale):

telithromycin

Gruppo terapeutico:

Antibacterials for systemic use,

Area terapeutica:

Sinusitis; Tonsillitis; Bronchitis, Chronic; Pharyngitis; Community-Acquired Infections; Pneumonia, Bacterial

Indicazioni terapeutiche:

When prescribing Ketek, consideration should be given to official guidance on the appropriate use ofantibacterial agents and the local prevalence of resistance.Ketek is indicated for the treatment of the following infections:In patients of 18 years and oldercommunity-acquired pneumonia, mild or moderate.when treating infections caused by known or suspected beta-lactam- and / or macrolide-resistant strains (according to history of patients or national and / or regional resistance data) covered by the antibacterial spectrum of telithromycin:acute exacerbation of chronic bronchitis;acute sinusitis;In patients of 12 years and oldertonsillitis / pharyngitis caused by Streptococcus pyogenes, as an alternative when beta-lactam antibiotics are not appropriate in countries / regions with a significant prevalence of macrolide-resistant S. pyogenes, when mediated by ermTR or mefA.

Dettagli prodotto:

Revision: 25

Stato dell'autorizzazione:

Withdrawn

Data dell'autorizzazione:

2001-07-09

Foglio illustrativo

                                24
B. PACKAGE LEAFLET
Medicinal product no longer authorised
25
PACKAGE LEAFLET: INFORMATION FOR THE USER
KETEK 400 MG FILM-COATED TABLETS
Telithromycin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Ketek is and what it is used for
2.
What you need to know before you take
_ _
Ketek
3.
How to take
_ _
Ketek
4.
Possible side effects
5.
How to store Ketek
6.
Contents of the pack and other information
1.
WHAT KETEK IS AND WHAT IT IS USED FOR
Ketek contains the active substance telithromycin.
Ketek is an antibiotic of the type macrolides. Antibiotics stop the
growth of bacteria which cause
infections.
Ketek is used to treat infections due to bacteria against which the
medicine is active.
-
In adults, Ketek is used to treat infections of the throat, infections
of the sinuses (hollow cavities
in the bones around the nose) and chest infections in patients with
long standing breathing
difficulties and lung infection (pneumonia).
-
In adolescents of 12 years and older, Ketek is used to treat
infections of the throat.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE KETEK
DO NOT TAKE KETEK:
-
if you are ALLERGIC to telithromycin, to any of the macrolide
antibiotics or to any of the other
ingredients of this medicine (listed in section 6). If in doubt, talk
to your doctor or pharmacist.
-
if you suffer from MYASTHENIA GRAVIS, a rare disease which causes
muscle weakness.
-
if you have had a liver disease (HEPATITIS and/or JAUNDICE) while
taking Ketek in the past.
-
if you are TAKING OTHER MEDICINES 
                                
                                Leggi il documento completo
                                
                            

Scheda tecnica

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Ketek 400 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 400 mg of telithromycin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Light orange, oblong, biconvex tablet, imprinted with ‘H3647’ on
one side and ‘400’ on the other.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
When prescribing Ketek, consideration should be given to official
guidance on the appropriate use of
antibacterial agents and the local prevalence of resistance (see also
sections 4.4 and 5.1).
Ketek is indicated for the treatment of the following infections:
_In patients of 18 years and older: _
• Community-acquired pneumonia, mild or moderate (see section 4.4).
• When treating infections caused by known or suspected beta-lactam
and/or macrolide resistant
strains (according to history of patients or national and/or regional
resistance data) covered by
the antibacterial spectrum of telithromycin (see sections 4.4 and
5.1):
-
Acute exacerbation of chronic bronchitis,
-
Acute sinusitis
_In patients of 12 years and older: _
• Tonsillitis/pharyngitis caused by S
_treptococcus pyogenes_
, as an alternative when beta lactam
antibiotics are not appropriate in countries/regions with a
significant prevalence of macrolide
resistant
_S. pyogenes_
, when mediated by ermTR or mefA (see sections 4.4 and 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 800 mg once a day i.e. two 400 mg tablets once
a day.
_In patients of 18 years and older, according to the indication, the
treatment regimen will be: _
-
Community-acquired pneumonia: 800 mg once a day for 7 to 10 days,
-
Acute exacerbation of chronic bronchitis: 800 mg once a day for 5
days,
-
Acute sinusitis: 800 mg once a day for 5 days,
-
Tonsillitis/pharyngitis caused by
_Streptococcus pyogenes:_
800 mg once a day for 5 days.
_In patients of 
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo bulgaro 19-06-2019
Scheda tecnica Scheda tecnica bulgaro 19-06-2019
Foglio illustrativo Foglio illustrativo spagnolo 19-06-2019
Scheda tecnica Scheda tecnica spagnolo 19-06-2019
Relazione pubblica di valutazione Relazione pubblica di valutazione spagnolo 19-06-2019
Foglio illustrativo Foglio illustrativo ceco 19-06-2019
Scheda tecnica Scheda tecnica ceco 19-06-2019
Foglio illustrativo Foglio illustrativo danese 19-06-2019
Scheda tecnica Scheda tecnica danese 19-06-2019
Foglio illustrativo Foglio illustrativo tedesco 19-06-2019
Scheda tecnica Scheda tecnica tedesco 19-06-2019
Foglio illustrativo Foglio illustrativo estone 19-06-2019
Scheda tecnica Scheda tecnica estone 19-06-2019
Foglio illustrativo Foglio illustrativo greco 19-06-2019
Scheda tecnica Scheda tecnica greco 19-06-2019
Foglio illustrativo Foglio illustrativo francese 19-06-2019
Scheda tecnica Scheda tecnica francese 19-06-2019
Relazione pubblica di valutazione Relazione pubblica di valutazione francese 19-06-2019
Foglio illustrativo Foglio illustrativo italiano 19-06-2019
Scheda tecnica Scheda tecnica italiano 19-06-2019
Relazione pubblica di valutazione Relazione pubblica di valutazione italiano 19-06-2019
Foglio illustrativo Foglio illustrativo lettone 19-06-2019
Scheda tecnica Scheda tecnica lettone 19-06-2019
Foglio illustrativo Foglio illustrativo lituano 19-06-2019
Scheda tecnica Scheda tecnica lituano 19-06-2019
Foglio illustrativo Foglio illustrativo ungherese 19-06-2019
Scheda tecnica Scheda tecnica ungherese 19-06-2019
Relazione pubblica di valutazione Relazione pubblica di valutazione ungherese 19-06-2019
Foglio illustrativo Foglio illustrativo maltese 19-06-2019
Scheda tecnica Scheda tecnica maltese 19-06-2019
Foglio illustrativo Foglio illustrativo olandese 19-06-2019
Scheda tecnica Scheda tecnica olandese 19-06-2019
Relazione pubblica di valutazione Relazione pubblica di valutazione olandese 19-06-2019
Foglio illustrativo Foglio illustrativo polacco 19-06-2019
Scheda tecnica Scheda tecnica polacco 19-06-2019
Foglio illustrativo Foglio illustrativo portoghese 19-06-2019
Scheda tecnica Scheda tecnica portoghese 19-06-2019
Relazione pubblica di valutazione Relazione pubblica di valutazione portoghese 19-06-2019
Foglio illustrativo Foglio illustrativo rumeno 19-06-2019
Scheda tecnica Scheda tecnica rumeno 19-06-2019
Foglio illustrativo Foglio illustrativo slovacco 19-06-2019
Scheda tecnica Scheda tecnica slovacco 19-06-2019
Relazione pubblica di valutazione Relazione pubblica di valutazione slovacco 19-06-2019
Foglio illustrativo Foglio illustrativo sloveno 19-06-2019
Scheda tecnica Scheda tecnica sloveno 19-06-2019
Foglio illustrativo Foglio illustrativo finlandese 19-06-2019
Scheda tecnica Scheda tecnica finlandese 19-06-2019
Relazione pubblica di valutazione Relazione pubblica di valutazione finlandese 19-06-2019
Foglio illustrativo Foglio illustrativo svedese 19-06-2019
Scheda tecnica Scheda tecnica svedese 19-06-2019
Foglio illustrativo Foglio illustrativo norvegese 19-06-2019
Scheda tecnica Scheda tecnica norvegese 19-06-2019
Foglio illustrativo Foglio illustrativo islandese 19-06-2019
Scheda tecnica Scheda tecnica islandese 19-06-2019
Foglio illustrativo Foglio illustrativo croato 19-06-2019
Scheda tecnica Scheda tecnica croato 19-06-2019

Cerca alert relativi a questo prodotto

Visualizza cronologia documenti